Characteristics of Study Participants Across Groups of Lateralization Based on Results Before and After Cosyntropin Stimulation
| . | U/U . | U/B . | B/U . | B/B . | Pa . |
|---|---|---|---|---|---|
| No. of participants (%) | 110 (49) | 32 (14) | 21 (10) | 59 (27) | |
| Age, median (range), y | 52 (45–59) | 49 (45–58) | 53 (43–61) | 53 (47–63) | 0.65 |
| Male sex, no. (%) | 64 (58) | 17 (53) | 15 (71) | 34 (58) | 0.62 |
| Race, no. (%) | 0.0003 | ||||
| White | 87 (55) | 14 (9) | 13 (8) | 44 (28) | |
| Black | 16 (30) | 17 (32) | 7 (13) | 13 (25) | |
| Asian | 3 (75) | 0 | 1 (25) | 0 | |
| LI, median, (IQR) | |||||
| Baseline | 16.5 (7.6–35.8) | 7.3b,c (5.3–12.4) | 2.2b,d (1.7–2.6) | 1.8b (1.2–2.4) | <0.0001 |
| 10 Min | 17.5 (8.5–39.3) | 2.5b (1.4–3.9) | 7.4b,c,d (4.4–13.2) | 1.6b,d (1.2–2.0) | <0.0001 |
| 20 Min | 18.1 (8.0–48.0) | 2.1b (1.6–2.8) | 8.2b,c,d (5.8–9.6) | 1.6b,d (1.2–2) | <0.0001 |
| Contralateral index, median, (IQR) | |||||
| Baseline | 0.4 (0.2–0.8) | 0.8b (0.4–1.7) | 0.9b (0.5–3.1) | 1.9b,d (0.8–4.2) | <0.0001 |
| 10 Min | 0.2 (0.1–0.4) | 1.1b (0.5–1.6) | 0.4c,d (0.1–0.5) | 1.1b (0.6–2) | <0.0001 |
| 20 Min | 0.2(0.1–0.4) | 1.0b (0.4–1.4) | 0.4c,d (0.2–0.7) | 1.1b (0.7–1.8) | <0.0001 |
| Baseline hormonal concentration, median, (IQR)e | |||||
| Aldo IVC | 26 (14–42) | 14b (10–22) | 19 (12–30) | 16b (11–27) | 0.0003 |
| Aldo AVD | 1145 (469–3049) | 774c (379–1560) | 151b,d (101–662) | 290b (98–796) | <0.0001 |
| Aldo AVN | 48 (25–109) | 73c (36–112) | 91b (58–356) | 172b (72–511) | <0.0001 |
| Cortisol IVC | 7 (5–10) | 5 (5–8) | 7 (4–9) | 7 (5–11) | 0.18 |
| Cortisol AVD | 27 (19–66) | 27 (20–57) | 24 (16–34) | 30 (19–55) | 0.53 |
| Cortisol AVN | 27 (19–66) | 26 (17–45) | 23 (17–47) | 31 (19–53) | 0.41 |
| 20-Min hormonal concentration after cosyntropin stimulation, median, (IQR) | |||||
| Aldo IVC | 46 (34–70) | 31b (24–48) | 40 (27–69) | 36b (24–52) | 0.0005 |
| Aldo AVD | 9362 (4673–18400) | 4732b (2210–7240) | 7260c (5500–11000) | 3730b (2200–5930) | <0.0001 |
| Aldo AVN | 462 (222–881) | 2060b (978–3100) | 1270b,c (332–2269) | 2595b (1350–3990) | <0.0001 |
| Cortisol IVC | 17 (15–20) | 18 (16–22) | 18 (13–21) | 18 (16–21) | 0.45 |
| Cortisol AVD | 1001 (684–1442) | 1462b (1011–1990) | 981c,d (641–1196) | 1369b (931–1670) | 0.0002 |
| Cortisol AVN | 1222 (809–1520) | 1350 (897–1739) | 1254 (1056–1494) | 1164 (940–1657) | 0.62 |
| Mutation (n = 61), no. | |||||
| KCNJ5 | 23 | — | 1 | — | |
| CACNA1D | 17 | 2 | 3 | — | |
| ATP1A1 | 7 | 1 | 2 | — | |
| ATP2B3 | 4 | — | — | — | |
| CTNNB1 | — | — | 1 | — | |
| . | U/U . | U/B . | B/U . | B/B . | Pa . |
|---|---|---|---|---|---|
| No. of participants (%) | 110 (49) | 32 (14) | 21 (10) | 59 (27) | |
| Age, median (range), y | 52 (45–59) | 49 (45–58) | 53 (43–61) | 53 (47–63) | 0.65 |
| Male sex, no. (%) | 64 (58) | 17 (53) | 15 (71) | 34 (58) | 0.62 |
| Race, no. (%) | 0.0003 | ||||
| White | 87 (55) | 14 (9) | 13 (8) | 44 (28) | |
| Black | 16 (30) | 17 (32) | 7 (13) | 13 (25) | |
| Asian | 3 (75) | 0 | 1 (25) | 0 | |
| LI, median, (IQR) | |||||
| Baseline | 16.5 (7.6–35.8) | 7.3b,c (5.3–12.4) | 2.2b,d (1.7–2.6) | 1.8b (1.2–2.4) | <0.0001 |
| 10 Min | 17.5 (8.5–39.3) | 2.5b (1.4–3.9) | 7.4b,c,d (4.4–13.2) | 1.6b,d (1.2–2.0) | <0.0001 |
| 20 Min | 18.1 (8.0–48.0) | 2.1b (1.6–2.8) | 8.2b,c,d (5.8–9.6) | 1.6b,d (1.2–2) | <0.0001 |
| Contralateral index, median, (IQR) | |||||
| Baseline | 0.4 (0.2–0.8) | 0.8b (0.4–1.7) | 0.9b (0.5–3.1) | 1.9b,d (0.8–4.2) | <0.0001 |
| 10 Min | 0.2 (0.1–0.4) | 1.1b (0.5–1.6) | 0.4c,d (0.1–0.5) | 1.1b (0.6–2) | <0.0001 |
| 20 Min | 0.2(0.1–0.4) | 1.0b (0.4–1.4) | 0.4c,d (0.2–0.7) | 1.1b (0.7–1.8) | <0.0001 |
| Baseline hormonal concentration, median, (IQR)e | |||||
| Aldo IVC | 26 (14–42) | 14b (10–22) | 19 (12–30) | 16b (11–27) | 0.0003 |
| Aldo AVD | 1145 (469–3049) | 774c (379–1560) | 151b,d (101–662) | 290b (98–796) | <0.0001 |
| Aldo AVN | 48 (25–109) | 73c (36–112) | 91b (58–356) | 172b (72–511) | <0.0001 |
| Cortisol IVC | 7 (5–10) | 5 (5–8) | 7 (4–9) | 7 (5–11) | 0.18 |
| Cortisol AVD | 27 (19–66) | 27 (20–57) | 24 (16–34) | 30 (19–55) | 0.53 |
| Cortisol AVN | 27 (19–66) | 26 (17–45) | 23 (17–47) | 31 (19–53) | 0.41 |
| 20-Min hormonal concentration after cosyntropin stimulation, median, (IQR) | |||||
| Aldo IVC | 46 (34–70) | 31b (24–48) | 40 (27–69) | 36b (24–52) | 0.0005 |
| Aldo AVD | 9362 (4673–18400) | 4732b (2210–7240) | 7260c (5500–11000) | 3730b (2200–5930) | <0.0001 |
| Aldo AVN | 462 (222–881) | 2060b (978–3100) | 1270b,c (332–2269) | 2595b (1350–3990) | <0.0001 |
| Cortisol IVC | 17 (15–20) | 18 (16–22) | 18 (13–21) | 18 (16–21) | 0.45 |
| Cortisol AVD | 1001 (684–1442) | 1462b (1011–1990) | 981c,d (641–1196) | 1369b (931–1670) | 0.0002 |
| Cortisol AVN | 1222 (809–1520) | 1350 (897–1739) | 1254 (1056–1494) | 1164 (940–1657) | 0.62 |
| Mutation (n = 61), no. | |||||
| KCNJ5 | 23 | — | 1 | — | |
| CACNA1D | 17 | 2 | 3 | — | |
| ATP1A1 | 7 | 1 | 2 | — | |
| ATP2B3 | 4 | — | — | — | |
| CTNNB1 | — | — | 1 | — | |
Abbreviations: aldo, aldosterone; AVD, dominant adrenal vein; AVN, nondominant adrenal vein; IQR, interquartile range.
Comparison across groups was performed by Kruskal-Wallis (P represents across group test) and Steel-Dwass all-pairs comparisons.
P < 0.05, compared with U/U.
P < 0.05, compared with B/B.
P < 0.05, compared with U/B.
Aldosterone concentrations are shown in ng/dL and cortisol concentrations in µg/dL.
Characteristics of Study Participants Across Groups of Lateralization Based on Results Before and After Cosyntropin Stimulation
| . | U/U . | U/B . | B/U . | B/B . | Pa . |
|---|---|---|---|---|---|
| No. of participants (%) | 110 (49) | 32 (14) | 21 (10) | 59 (27) | |
| Age, median (range), y | 52 (45–59) | 49 (45–58) | 53 (43–61) | 53 (47–63) | 0.65 |
| Male sex, no. (%) | 64 (58) | 17 (53) | 15 (71) | 34 (58) | 0.62 |
| Race, no. (%) | 0.0003 | ||||
| White | 87 (55) | 14 (9) | 13 (8) | 44 (28) | |
| Black | 16 (30) | 17 (32) | 7 (13) | 13 (25) | |
| Asian | 3 (75) | 0 | 1 (25) | 0 | |
| LI, median, (IQR) | |||||
| Baseline | 16.5 (7.6–35.8) | 7.3b,c (5.3–12.4) | 2.2b,d (1.7–2.6) | 1.8b (1.2–2.4) | <0.0001 |
| 10 Min | 17.5 (8.5–39.3) | 2.5b (1.4–3.9) | 7.4b,c,d (4.4–13.2) | 1.6b,d (1.2–2.0) | <0.0001 |
| 20 Min | 18.1 (8.0–48.0) | 2.1b (1.6–2.8) | 8.2b,c,d (5.8–9.6) | 1.6b,d (1.2–2) | <0.0001 |
| Contralateral index, median, (IQR) | |||||
| Baseline | 0.4 (0.2–0.8) | 0.8b (0.4–1.7) | 0.9b (0.5–3.1) | 1.9b,d (0.8–4.2) | <0.0001 |
| 10 Min | 0.2 (0.1–0.4) | 1.1b (0.5–1.6) | 0.4c,d (0.1–0.5) | 1.1b (0.6–2) | <0.0001 |
| 20 Min | 0.2(0.1–0.4) | 1.0b (0.4–1.4) | 0.4c,d (0.2–0.7) | 1.1b (0.7–1.8) | <0.0001 |
| Baseline hormonal concentration, median, (IQR)e | |||||
| Aldo IVC | 26 (14–42) | 14b (10–22) | 19 (12–30) | 16b (11–27) | 0.0003 |
| Aldo AVD | 1145 (469–3049) | 774c (379–1560) | 151b,d (101–662) | 290b (98–796) | <0.0001 |
| Aldo AVN | 48 (25–109) | 73c (36–112) | 91b (58–356) | 172b (72–511) | <0.0001 |
| Cortisol IVC | 7 (5–10) | 5 (5–8) | 7 (4–9) | 7 (5–11) | 0.18 |
| Cortisol AVD | 27 (19–66) | 27 (20–57) | 24 (16–34) | 30 (19–55) | 0.53 |
| Cortisol AVN | 27 (19–66) | 26 (17–45) | 23 (17–47) | 31 (19–53) | 0.41 |
| 20-Min hormonal concentration after cosyntropin stimulation, median, (IQR) | |||||
| Aldo IVC | 46 (34–70) | 31b (24–48) | 40 (27–69) | 36b (24–52) | 0.0005 |
| Aldo AVD | 9362 (4673–18400) | 4732b (2210–7240) | 7260c (5500–11000) | 3730b (2200–5930) | <0.0001 |
| Aldo AVN | 462 (222–881) | 2060b (978–3100) | 1270b,c (332–2269) | 2595b (1350–3990) | <0.0001 |
| Cortisol IVC | 17 (15–20) | 18 (16–22) | 18 (13–21) | 18 (16–21) | 0.45 |
| Cortisol AVD | 1001 (684–1442) | 1462b (1011–1990) | 981c,d (641–1196) | 1369b (931–1670) | 0.0002 |
| Cortisol AVN | 1222 (809–1520) | 1350 (897–1739) | 1254 (1056–1494) | 1164 (940–1657) | 0.62 |
| Mutation (n = 61), no. | |||||
| KCNJ5 | 23 | — | 1 | — | |
| CACNA1D | 17 | 2 | 3 | — | |
| ATP1A1 | 7 | 1 | 2 | — | |
| ATP2B3 | 4 | — | — | — | |
| CTNNB1 | — | — | 1 | — | |
| . | U/U . | U/B . | B/U . | B/B . | Pa . |
|---|---|---|---|---|---|
| No. of participants (%) | 110 (49) | 32 (14) | 21 (10) | 59 (27) | |
| Age, median (range), y | 52 (45–59) | 49 (45–58) | 53 (43–61) | 53 (47–63) | 0.65 |
| Male sex, no. (%) | 64 (58) | 17 (53) | 15 (71) | 34 (58) | 0.62 |
| Race, no. (%) | 0.0003 | ||||
| White | 87 (55) | 14 (9) | 13 (8) | 44 (28) | |
| Black | 16 (30) | 17 (32) | 7 (13) | 13 (25) | |
| Asian | 3 (75) | 0 | 1 (25) | 0 | |
| LI, median, (IQR) | |||||
| Baseline | 16.5 (7.6–35.8) | 7.3b,c (5.3–12.4) | 2.2b,d (1.7–2.6) | 1.8b (1.2–2.4) | <0.0001 |
| 10 Min | 17.5 (8.5–39.3) | 2.5b (1.4–3.9) | 7.4b,c,d (4.4–13.2) | 1.6b,d (1.2–2.0) | <0.0001 |
| 20 Min | 18.1 (8.0–48.0) | 2.1b (1.6–2.8) | 8.2b,c,d (5.8–9.6) | 1.6b,d (1.2–2) | <0.0001 |
| Contralateral index, median, (IQR) | |||||
| Baseline | 0.4 (0.2–0.8) | 0.8b (0.4–1.7) | 0.9b (0.5–3.1) | 1.9b,d (0.8–4.2) | <0.0001 |
| 10 Min | 0.2 (0.1–0.4) | 1.1b (0.5–1.6) | 0.4c,d (0.1–0.5) | 1.1b (0.6–2) | <0.0001 |
| 20 Min | 0.2(0.1–0.4) | 1.0b (0.4–1.4) | 0.4c,d (0.2–0.7) | 1.1b (0.7–1.8) | <0.0001 |
| Baseline hormonal concentration, median, (IQR)e | |||||
| Aldo IVC | 26 (14–42) | 14b (10–22) | 19 (12–30) | 16b (11–27) | 0.0003 |
| Aldo AVD | 1145 (469–3049) | 774c (379–1560) | 151b,d (101–662) | 290b (98–796) | <0.0001 |
| Aldo AVN | 48 (25–109) | 73c (36–112) | 91b (58–356) | 172b (72–511) | <0.0001 |
| Cortisol IVC | 7 (5–10) | 5 (5–8) | 7 (4–9) | 7 (5–11) | 0.18 |
| Cortisol AVD | 27 (19–66) | 27 (20–57) | 24 (16–34) | 30 (19–55) | 0.53 |
| Cortisol AVN | 27 (19–66) | 26 (17–45) | 23 (17–47) | 31 (19–53) | 0.41 |
| 20-Min hormonal concentration after cosyntropin stimulation, median, (IQR) | |||||
| Aldo IVC | 46 (34–70) | 31b (24–48) | 40 (27–69) | 36b (24–52) | 0.0005 |
| Aldo AVD | 9362 (4673–18400) | 4732b (2210–7240) | 7260c (5500–11000) | 3730b (2200–5930) | <0.0001 |
| Aldo AVN | 462 (222–881) | 2060b (978–3100) | 1270b,c (332–2269) | 2595b (1350–3990) | <0.0001 |
| Cortisol IVC | 17 (15–20) | 18 (16–22) | 18 (13–21) | 18 (16–21) | 0.45 |
| Cortisol AVD | 1001 (684–1442) | 1462b (1011–1990) | 981c,d (641–1196) | 1369b (931–1670) | 0.0002 |
| Cortisol AVN | 1222 (809–1520) | 1350 (897–1739) | 1254 (1056–1494) | 1164 (940–1657) | 0.62 |
| Mutation (n = 61), no. | |||||
| KCNJ5 | 23 | — | 1 | — | |
| CACNA1D | 17 | 2 | 3 | — | |
| ATP1A1 | 7 | 1 | 2 | — | |
| ATP2B3 | 4 | — | — | — | |
| CTNNB1 | — | — | 1 | — | |
Abbreviations: aldo, aldosterone; AVD, dominant adrenal vein; AVN, nondominant adrenal vein; IQR, interquartile range.
Comparison across groups was performed by Kruskal-Wallis (P represents across group test) and Steel-Dwass all-pairs comparisons.
P < 0.05, compared with U/U.
P < 0.05, compared with B/B.
P < 0.05, compared with U/B.
Aldosterone concentrations are shown in ng/dL and cortisol concentrations in µg/dL.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
